BioCentury
ARTICLE | Company News

Navidea, AstraZeneca deal

January 21, 2013 8:00 AM UTC

Navidea said it and AstraZeneca added rights to two beta amyloid imaging agents - AZD2184 and AZD2995 - to a 2011 deal granting Navidea (formerly Neoprobe Corp.) exclusive, worldwide rights to AZD4694 to detect Alzheimer's disease. The new compounds are carbon 11-labeled PET radioligand tracers discovered by AstraZeneca in collaboration with the Karolinska Institute (Stockholm, Sweden). The partners did not disclose financial terms and could not be reached for details (see BioCentury, Dec. 19, 2011). ...